References
- Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initia-tive randomized controlled trial. J Am Med Assoc 2002;288:321–33
- Fletcher SW, Colditz GA. Failure of estrogen plus progestin therapy for prevention. J Am Med Assoc 2002;288:366–8
- Genazzani AR, Gadducci A, Gambacciani M. Controversial issues in climacteric medicine II. Hormone replacement therapy and cancer. Inter-national Menopause Society Expert Workshop, 9–12 June 2001, Opera del Duomo, Pisa, Italy. Climacteric 2001 ;4: 181–93
- Genazzani AR, Gambacciani M. Hormone replacement therapy: the perspectives for the 21st century. Cardiovascular disease and hormone replacement therapy. International Menopause Society Expert Workshop, 13–16 October 2000, Royal Society of Medicine, London, UK. Climacteric 2000;3: 233–40
- Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. J Am Med Assoc 2002;287:2668–76
- Gambacciani M, Monteleone P, Genazzani AR. Low-dose hormone replacement therapy: effects on bone. Climacteric 2002;5:135–9
- Ettinger B. Personal perspective on low-dosage estrogen therapy for postmenopausal women. Menopause 1999;6:273–6
- Lobo RA, Whitehead MI. Is low-dose hormone replacement therapy for postmenopausal women efficacious and desirable? Climacteric 2001;4:110–19
- Gambacciani M, Genazzani AR. Hormone replacement therapy: the benefits in tailoring the regimen and dose. Maturitas 2001;40:195–201
- Grady D, Herrington D, Bittner V, et al., for the HERS Research Group. Heart and estrogen/ progestin replacement study follow-up (HERS II): Part 1. Cardiovascular outcomes during 6.8 years of hormone therapy. JAm Med Assoc 2002;288: 49–57
- Hulley S, Furberg C, Barrett-Connor E, et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/ progestin Replacement Study follow-up (HERS II). J Am Med Assoc 2002;288: 58–66